NASDAQ:CTXR Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free CTXR Stock Alerts $0.66 -0.07 (-9.53%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.64▼$0.6950-Day Range$0.66▼$1.0352-Week Range$0.60▼$1.56Volume2.78 million shsAverage Volume1.21 million shsMarket Capitalization$105.77 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Citius Pharmaceuticals alerts: Email Address Citius Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside501.7% Upside$4.00 Price TargetShort InterestBearish8.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.21) to $0.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.99 out of 5 starsMedical Sector813th out of 914 stocksPharmaceutical Preparations Industry376th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingCitius Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCitius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.29% of the outstanding shares of Citius Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.Change versus previous monthShort interest in Citius Pharmaceuticals has recently increased by 6.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCitius Pharmaceuticals does not currently pay a dividend.Dividend GrowthCitius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTXR. Previous Next 1.9 News and Social Media Coverage News SentimentCitius Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Citius Pharmaceuticals this week, compared to 1 article on an average week.Search Interest9 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows10 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.88% of the stock of Citius Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($0.21) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Citius Pharmaceuticals is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Citius Pharmaceuticals is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCitius Pharmaceuticals has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Citius Pharmaceuticals Stock (NASDAQ:CTXR)Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Read More CTXR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTXR Stock News HeadlinesApril 26, 2024 | prnewswire.comCitius Pharmaceuticals Announces $15 Million Registered Direct OfferingApril 14, 2024 | seekingalpha.comCTXR Citius Pharmaceuticals, Inc.April 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 11, 2024 | prnewswire.comCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaApril 4, 2024 | prnewswire.comCitius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceMarch 20, 2024 | finance.yahoo.comCTXR Apr 2024 7.500 putMarch 20, 2024 | finance.yahoo.comCTXR May 2024 2.500 callMarch 20, 2024 | edition.cnn.comCitius Pharmaceuticals IncApril 27, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 18, 2024 | msn.comCitius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatmentMarch 18, 2024 | markets.businessinsider.comCitius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick FactsMarch 18, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaMarch 7, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramMarch 7, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramFebruary 26, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationFebruary 26, 2024 | prnewswire.comCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationFebruary 23, 2024 | finance.yahoo.comCitius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesFebruary 14, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateFebruary 14, 2024 | markets.businessinsider.comBuy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug ExclusivityFebruary 14, 2024 | finance.yahoo.comCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaFebruary 14, 2024 | prnewswire.comCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaJanuary 23, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsJanuary 4, 2024 | markets.businessinsider.comStrong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology SpinoutJanuary 2, 2024 | finanznachrichten.deCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage CathetersJanuary 2, 2024 | baystreet.caCitius Ekes out Gains as Trials EndJanuary 2, 2024 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business UpdateJanuary 2, 2024 | finance.yahoo.comCitius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage CathetersSee More Headlines Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/27/2024Next Earnings (Estimated)5/10/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTXR CUSIPN/A CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+501.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.63% Return on Assets-36.74% Debt Debt-to-Equity RatioN/A Current Ratio5.06 Quick Ratio5.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book1.15Miscellaneous Outstanding Shares159,100,000Free Float135,231,000Market Cap$105.77 million OptionableOptionable Beta1.45 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Leonard L. Mazur (Age 79)Co-Founder, CEO, Chairman & Secretary Comp: $676.88kMr. Myron Z. Holubiak (Age 77)Co-Founder & Executive Vice Chairman Comp: $641.25kDr. Myron S. Czuczman M.D. (Age 64)Executive VP & Chief Medical Officer Comp: $571.38kMr. Jaime Bartushak (Age 56)Chief Business Officer, CFO & Chief Accounting Officer Comp: $527.97kMr. Gary F. Talarico (Age 69)Executive Vice President of Operations Ms. Ilanit AllenVice President of Investor Relations & Corporate CommunicationsDr. Alan Lader Ph.D.Senior VP and Head of Clinical Operations & Quality AssuranceMr. Dhananjay G. Wadekar (Age 70)Senior Vice President of Business Strategy Mr. Kelly Creighton Ph.D.Executive Vice President of Chemistry, Manufacturing & ControlsMr. Nikolas BurlewExecutive Vice President of Quality AssuranceMore ExecutivesKey CompetitorsRepare TherapeuticsNASDAQ:RPTXEmergent BioSolutionsNYSE:EBSKaryopharm TherapeuticsNASDAQ:KPTIGlycoMimeticsNASDAQ:GLYCRelmada TherapeuticsNASDAQ:RLMDView All CompetitorsInstitutional OwnershipWealth Advisory Solutions LLCBought 151,000 shares on 4/23/2024Ownership: 0.095%View All Institutional Transactions CTXR Stock Analysis - Frequently Asked Questions Should I buy or sell Citius Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CTXR shares. View CTXR analyst ratings or view top-rated stocks. What is Citius Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 12 month price targets for Citius Pharmaceuticals' stock. Their CTXR share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 501.7% from the stock's current price. View analysts price targets for CTXR or view top-rated stocks among Wall Street analysts. How have CTXR shares performed in 2024? Citius Pharmaceuticals' stock was trading at $0.7565 at the beginning of 2024. Since then, CTXR shares have decreased by 12.1% and is now trading at $0.6648. View the best growth stocks for 2024 here. Are investors shorting Citius Pharmaceuticals? Citius Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 13,190,000 shares, an increase of 6.1% from the March 31st total of 12,430,000 shares. Based on an average daily volume of 849,900 shares, the short-interest ratio is presently 15.5 days. View Citius Pharmaceuticals' Short Interest. When is Citius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CTXR earnings forecast. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.13 by $0.19. When did Citius Pharmaceuticals' stock split? Shares of Citius Pharmaceuticals reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE). Who are Citius Pharmaceuticals' major shareholders? Citius Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wealth Advisory Solutions LLC (0.09%). View institutional ownership trends. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTXR) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
